Post‐mastectomy surveillance of
            <i>BRCA1</i>
            /
            <i>BRCA</i>
            2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients

Kanana, Nayroz; David, Meirav A Ben; Nissan, Noam; Yagil, Yael; Shalmon, Anat; Halshtok, Osnat; Gotlieb, Michael; Faermann, Renata; Klang, Eyal; Samoocha, David; Yassin, M.M.; Davidson, Tima; Zippel, Dov; Feldman, Dana; Friedman, Eitan; Kaidar‐Person, Orit; Levy, Miri Sklair

doi:10.1111/tbj.14190

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported germline I482* variant in BRCA1 gene was associated with familial ovarian cancer predisposition in German and Japanese populations [ 20 , 21 ]. Q1756fs*74 in BRCA1 gene was also observed in Italian, Israel, USA, Brazilian, Ukrainian, Polish and Czech population with familial breast and ovarian cancer [ [22] , [23] , [24] , [25] , [26] , [27] ]. The 3rd most frequent was Q934* which had been associated with epithelial ovarian cancer in Turkish population and; familial and non-familial ovarian cancer in Japanese and Argentinian [ [28] , [29] , [30] , [31] ].…”

Section: Discussionmentioning

confidence: 92%

Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey

Bişgin¹,

Sağ²,

Doğan³

et al. 2022

The Breast

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey

Bişgin¹,

Sağ²,

Doğan³

et al. 2022

The Breast

View full text Add to dashboard Cite

“…The current guidelines recommend continued annual chest wall examination after RRM, as the low residual risk does not appear to justify routine postmastectomy imaging. In one Israeli cohort study of 237 BRCA1/2 carriers, Kanana et al reported a surveillance protocol of physical examination with alternating ultrasound or MRI imaging every 6 months following RRM [110]. After 10-year surveillance, no breast cancers were diagnosed in 53 unaffected carriers who underwent bilateral RRM; however, 7% of 184 affected carriers developed a local recurrence.…”

Section: Postmastectomy Surveillancementioning

confidence: 99%

Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy

Wong,

Apostolova,

Eisenberg

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Female BRCA1/2 and PALB2 germline pathogenic variant carriers have an increased lifetime risk of breast cancer and may wish to consider risk-reducing mastectomy (RRM) for surgical prevention. Quantifying the residual lifetime risk and absolute benefit from RRM requires careful consideration of a patient’s age, pathogenic variant, and their personal history of breast or ovarian cancer. Historically, patients have been counselled that RRM does not necessarily prolong survival relative to high-risk surveillance, although recent studies suggest a possible survival benefit of RRM in BRCA1 carriers. The uptake of RRM has increased dramatically over the last several decades yet varies according to sociodemographic factors and geographic region. The increased adoption of nipple-sparing mastectomy techniques, ability to avoid axillary staging, and availability of reconstructive options for most germline pathogenic variant carriers has helped to minimize the morbidity of RRM. Preoperative discussions should include evidence regarding postmastectomy sensation, the potential for supplemental surgery, pregnancy-related chest wall changes, and the need for continued clinical surveillance. Approaches that include sensation preservation and robotic nipple-sparing mastectomy are an area of evolving research that may be more widely adopted in the future.

show abstract

A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction

Kaidar-Person,

Faermann,

Polikar

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

Introduction Different types of mastectomies leave different amounts of residual breast tissue. The significance of the residual breast volume (RBV) is not clear. Therefore, we developed an MRI tool that allows to easily assess the RBV. In this study we evaluated factors associated with RBV after skin or nipple sparing mastectomy (SSM/NSM) in breast cancer BRCA pathogenic variant (PV) carriers who underwent both therapeutic and risk reducing SSM/NSM and its relation to breast cancer outcomes using an innovative MRI-based tool. Methods Data of breast cancer BRCA PV who were treated between 2006 and 2020 were retrieved from of the oncogenetics unit databases. Only patients who underwent SSM/NSM and had a postoperative breast MRI available for analysis were included. Data collected included demographics, clinicopathological features, and outcomes. The MRI tool was developed by a breast cancer imaging laboratory. A logistic regression test and 95% confidence interval (CI) were used to assess the associated risk of increased RBV. A forward stepwise linear regression was used to correlate tumour-patient specific factors and RBV, and a Kaplan–Meier curve to show the probability of locoregional relapse. Results A total of 84 patients undergoing 89 mastectomies were included. At a median follow-up of 98 months, 5 local, 2 regional, and 4 distant recurrences were observed. RBV was not significantly related with breast cancer outcomes (p value = NS). A higher body mass index (BMI) was associated with a higher RBV (p < 0.0001). A larger number of involved axillary nodes was associated with a smaller RBV (p = 0.025). The RBV on the risk-reducing mastectomy side was significantly higher compared to the breast cancer side (p value = 0.007). Local recurrences occurred in the vicinity of the primary tumour.

show abstract

Post‐mastectomy surveillance of BRCA1 / BRCA 2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients

Cited by 5 publications

References 20 publications

Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey

Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey

Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy

A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction

Contact Info

Product

Resources

About